Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860157 | 1.00 | BTK (1.00) | BTK | |
| SCHEMBL13860105 | 0.88 | BTK (1.00) | BTK | |
| SCHEMBL13860104 | 0.88 | BTK (1.00) | BTK | |
| SCHEMBL18533099 | 0.86 | BTK (0.75) | BTK | |
| SCHEMBL15516879 | 0.83 | BTK (0.70) | BTK | |
| SCHEMBL13860304 | 0.81 | BTK (1.00) | BTK | |
| SCHEMBL13861382 | 0.81 | BTK (1.00) | BTK | |
| SCHEMBL15516711 | 0.80 | BTK (0.77) | BTK | |
| SCHEMBL15516709 | 0.80 | BTK (0.77) | BTK | |
| SCHEMBL18043080 | 0.80 | BTK (0.66) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PRINCIPIA BIOPHARMA INC. | 2016-02-18 | — | — | US | claimed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | claimed |
| US-20150182530-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-02 | — | — | US | claimed |
| EP-2710005-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2012158764-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | claimed |
| US-10946008-B2 | Treatment of pemphigus | PRINCIPIA BIOPHARMA INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-107257686-B | Treatment of pemphigus | 普林斯匹亚生物制药公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20200101059-A1 | TREATMENT OF PEMPHIGUS | PRINCIPIA BIOPHARMA INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10485797-B2 | Treatment of pemphigus | PRINCIPIA BIOPHARMA INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20180050027-A1 | TREATMENT OF PEMPHIGUS | PRINCIPIA BIOPHARMA INC. | 2018-02-22 | — | — | US | disclosed |
| EP-3233103-A1 | TREATMENT OF PEMPHIGUS | PRINCIPIA BIOPHARMA, INC. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9572811-B2 | Treatment of dry eye | PRINCIPIA BIOPHARMA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014022569-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014022569-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2014-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885 |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PTMS, SSB, HDAC6 | BTK 156/4885 |
| US-20200101059-A1 | TREATMENT OF PEMPHIGUS | BTK, PRKACA, PRKDC | BTK 1/4885 |
| US-20180050027-A1 | TREATMENT OF PEMPHIGUS | BTK, PRKACA, PRKDC | BTK 1/4885 |
| US-10946008-B2 | Treatment of pemphigus | BTK, PRKACA, PRKDC | BTK 1/4885 |
| US-20150182530-A1 | TREATMENT OF DRY EYE | BTK, SYK, LYN | BTK 1/4885 |
| US-10485797-B2 | Treatment of pemphigus | BTK, PRKACA, PRKDC | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.